Filing Flows

Filing Flows › 8-K events › Silo Pharma

Silo Pharma: entry into a material definitive agreement

Form 8-K filed Nov 6, 2026 · items 1.01, 3.02

What the filing says

On November 5, 2026, Silo Pharma, Inc. (the “Company”) entered into securities purchase agreements (the “Purchase Agreements”) with certain accredited investors (“the “Purchasers”) for the issuance and sale in a private placement (the “Private Placement”) of (i) 136,005 shares (the “Shares”) of the Company’s common sto

Read the filing on SEC EDGAR →

What usually followsAcross 23,525 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Item 3.02: +0.1% next session across 2,750. Every item ranked →

What this kind of filing means

Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.

Other recent share offerings

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.